5 articles tagged with #pharmaceutical-research. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Bittensor's SN68 subnet is being leveraged by Metanova Labs to accelerate pharmaceutical research and development through decentralized AI infrastructure. While this application demonstrates potential to democratize drug discovery and reduce costs, significant validation challenges remain before decentralized approaches can meaningfully compete with traditional pharma workflows.
Researchers introduce MuCO, a generative AI method for modeling cyclic peptide structures through multi-stage conformation optimization. The approach outperforms existing methods in stability, diversity, and efficiency, offering significant implications for computational drug discovery and peptide-based therapeutic development.
Two AI-based science assistants have demonstrated success in drug-retargeting tasks, with both tools capable of generating hypotheses and one additionally analyzing relevant data. This advancement showcases AI's growing role in accelerating pharmaceutical research and drug discovery processes.
Researchers have developed NaFM, a foundation model pretrained specifically for natural products using contrastive and masked graph learning objectives. The model achieves state-of-the-art results across drug discovery tasks including taxonomy classification and virtual screening, addressing limitations in existing deep learning approaches that lack generalizability for natural product research.
Professor James Collins discusses how collaboration has been central to his research combining computational predictions with experimental platforms to accelerate therapeutic drug discovery and design using AI technologies.
